Dermatology Xagena
The statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase III studies. ESTEEM 1 ...
New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...
Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program were presented at the 23rd European Academy of Dermatology and Venereolog ...
Apremilast ( Otezla ), a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-inflammatory cytokine production. Apremilast's effect on patient-reported outcomes ( PROs ) i ...
Apremilast ( Otezla ), a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily ha ...
Results from two pivotal phase 3 trials evaluating Deucravacitinib, an oral, selective tyrosine kinase 2 ( TYK2 ) inhibitor, for the treatment of patients with moderate to severe plaque psoriasis, wer ...